Evidence map›Paper›PMID 31381842›Full record

ReviewStem cells (Dayton, Ohio)2020

Preclinical translation of exosomes derived from mesenchymal stem/stromal cells.

Fanny M Elahi, D Gregory Farwell, Jan A Nolta, Johnathon D Anderson

Abstract readReview
In one paragraph

Review in Stem cells (Dayton, Ohio), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fanny M ElahiDepartment of Neurology, University of California San Francisco, San Francisco, California.
D Gregory FarwellDepartment of Otolaryngology, University of California Davis, Sacramento, California.
Jan A NoltaInstitute for Regenerative Cures, University of California Davis, Sacramento, California.
Johnathon D AndersonDepartment of Otolaryngology, University of California Davis, Sacramento, California.ORCID 0000-0001-5404-2298

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
Institutional Career Development Core (KL2)KL2TR001859 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HOLMES, JAMES F. · 2016 to 2025
$10.1M
Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasT32AG023481 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRUCE L MILLER, HOWARD J ROSEN · 2005 to 2026
$7.4M
Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
West Coast Metabolomics Center for Compound IdentificationU2CES030158 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FIEHN, OLIVER · 2018 to 2021
$4.1M
Direct cell to cell transfer of microRNA for tissue repairR01GM099688 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2011 to 2015
$2.7M
Training Program in Biomolecular TechnologyT32GM008799 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI LEACH, J. KENT · 2002 to 2016
$2.4M
Multimodal Imaging in Frontotemporal DegenerationK24AG045333 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2013 to 2023
$1.9M
NCATS NIH HHS KL2 TR001859NCATS NIH HHS UL1 TR001860NHLBI NIH HHS T32 HL086350NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG019724NIA NIH HHS T32 AG023481NIEHS NIH HHS U2C ES030158NIGMS NIH HHS R01 GM099688NIGMS NIH HHS T32 GM008799
6 · The paper itself

Abstract

Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the horizontal transfer of various macromolecules previously believed to be cell-autonomous in nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid membrane-associated factors. Exosomes derived from mesenchymal stem/stromal cells (MSCs) appear to be particularly beneficial for enhancing recovery in various models of disease. To date, there have been more than 200 preclinical studies of exosome-based therapies in a number of different animal models. Despite a growing number of studies reporting the therapeutic properties of MSC-derived exosomes, their underlying mechanism of action, pharmacokinetics, and scalable manufacturing remain largely outstanding questions. Here, we review the global trends associated with preclinical development of MSC-derived exosome-based therapies, including immunogenicity, source of exosomes, isolation methods, biodistribution, and disease categories tested to date. Although the in vivo data assessing the therapeutic properties of MSC-exosomes published to date are promising, several outstanding questions remain to be answered that warrant further preclinical investigation.

Indexed as

Cells, CulturedExosomesHumansMesenchymal Stem Cellsexosomesextracellular vesiclesmesenchymal stem cellsmesenchymal stromal cellsmicrovesicles

Identifiers

PMID31381842
PMCPMC7004029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.